Medpace Holdings CEO August J. Troendle sells $6.75m in stock

CEO and 10% owner of Medpace Holdings, August J. Troendle, divested shares of the company’s stock, amounting to $6.75 million. This occurred on September 17, 2026, when Troendle disposed of 10,880 shares. The shares were sold at a weighted average price of $620.40, with each transaction costing between $620.00 and $622.21 per share.

The sale was made via a limit order that Mr. Troendle placed during an open window period. The company's stock has risen 37% over the past six months, leading to a market capitalization of $17.27 billion. Post this sale, Troendle directly owns 504,273 shares and indirectly owns 4,733,019 shares through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.

He disclaims interest in the indirectly held securities, apart from his financial stake. Recently, Medpace Holdings outperformed expectations in its second-quarter results for 2026, reporting diluted earnings of $4.25 per share and revenue of $707.3 million, both exceeding forecasts. Revenue climbed 17.2% year-over-year, while diluted earnings per share surged 37.1%.

The company's net new business awards rose by 28.2% to $795.7 million, resulting in a book-to-bill ratio of 1.13x. Following the positive quarter, BMO Capital raised its price target for Medpace to $600, while Jefferies maintained a Hold rating with a $560 target. TD Cowen also increased its price target to $492, acknowledging Medpace's strong business-to-business trends, while acknowledging potential revenue challenges in 2027.